Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs.

Pathology, research and practice - 1 Nov 2022

Roessner Albert, Franke Sabine, Schreier Julian, Ullmann Sarah, Karras Franziska, Jechorek Doerthe

Abstract excerpt

The detection of mutations of isocitrate dehydrogenase 1 and 2 (IDH 1/2) as tumor driver genes in chondromas and chondrosarcomas more than ten years ago was a first major step for better understanding the molecular carcinogenenesis of these rare mesenchymal tumors. Within the TCA cycle, wild-typ IDH1/2 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG). IDH mutations catalyze the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chondrosarcoma

Share to Epigenesis, Genetic

Share to Isocitrate Dehydrogenase

Share to Ketoglutaric Acids

Share to MicroRNAs

Share to Mutation

Source

Identifiers

PMID: 36274381
DOI: 10.1016/j.prp.2022.154172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs.PMID 36274381Read ↗

Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.Semantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.Semantic proximity Read ↗

IDH Mutations in Chondrosarcoma: Case Closed or Not?Semantic proximity Read ↗

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in ChondrosarcomaSemantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future PerspectivesSemantic proximity Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d ‐2‐hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcomaSemantic proximity Read ↗

Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.